Press release
2021 Antisense & RNAi Therapeutics Market Industry Key Players, Trends, Demand Analysis Forecast to 2030
Antisense & RNAi Therapeutics Market
The global antisense & rnai therapeutics market is expected to grow from $1.11 billion in 2020 to $1.2 billion in 2021 at a compound annual growth rate (CAGR) of 8.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1.79 billion in 2025 at a CAGR of 11%.
The Business Research Company offers "Antisense & RNAi Therapeutics Global Market Report 2021" in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by country. It also compares the market’s historic and forecast growth, and highlights important trends and strategies that players in the market can adopt.
Place a DIRECT PURCHASE ORDER of the report @ https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3389
The antisense & RNAi therapeutics market consists of sales of antisense & RNAi therapeutics products and related services by entities (organizations, sole traders and partnerships) that develop antisense & RNAi therapeutics to treat various diseases. RNA interference (RNAi)-based and RNA-based antisense oligonucleotide therapies are advanced methods used for the treatment of various respiratory diseases including chronic obstructive pulmonary disease (COPD) and asthma. In addition to this, antisense & RNAi therapeutics finds its application in curing cancer, infectious diseases, cardiovascular diseases, and genetic disorders.
Some of the key players involved in the Antisense & RNAi Therapeutics Market are Alnylam Pharmaceuticals, Benitec Biopharma Ltd., Gene Signal, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Marina Biosciences, Quark Pharmaceuticals, Sanofi S.A
The countries covered in the global Antisense & RNAi Therapeutics Market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, Vietnam.
The regions covered in the global Antisense & RNAi Therapeutics Market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Antisense & RNAi Therapeutics Market Segmentation:
1) By Technology: RNA Interference, Antisense RNA
2) By Route of Administration: Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Intraperitoneal Injections, Topical Delivery, Other Delivery Methods
3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other
Browse Complete Report @ https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-market-global-report-2020-30-covid-19-growth-and-change
A Few Points From The Table Of Contents
1. Executive Summary
2. Antisense & RNAi Therapeutics Market Characteristics
3. Antisense & RNAi Therapeutics Market Trends And Strategies
4. Impact Of COVID-19 On Antisense & RNAi Therapeutics
5. Antisense & RNAi Therapeutics Market Size And Growth
....
27. Antisense & RNAi Therapeutics Market Competitive Landscape And Company Profiles
28. Antisense & RNAi Therapeutics Pipeline Analysis
29. Key Mergers And Acquisitions In The Antisense & RNAi Therapeutics Market
30. Antisense & RNAi Therapeutics Market Future Outlook and Potential Analysis
31. Appendix
The report covers the trends and market dynamics of the Antisense & RNAi Therapeutics Market in major countries - Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The report also includes consumer surveys and various future opportunities for the market.
Request for a Sample Copy of this report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp
Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow our blog: http://blog.tbrc.info/
About Us:
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets after WHO declared COVID-19 as a pandemic.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release 2021 Antisense & RNAi Therapeutics Market Industry Key Players, Trends, Demand Analysis Forecast to 2030 here
News-ID: 2251842 • Views: …
More Releases from The Business research company
2024 Global Veterinary Hematology Analyzers Market Size, Share, Trends And Growt …
"The veterinary hematology analyzers market size has grown strongly in recent years. It will grow from $0.9 billion in 2023 to $0.98 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increase in pet ownership, advancements in veterinary medicine, prevalence of animal diseases, growing awareness of animal health, expansion of veterinary services.
The veterinary hematology analyzers…
Global EV Platform Market 2024 : SWOT Analysis Of Key Driving Factors For Growin …
"The ev platform market size has grown exponentially in recent years. It will grow from $9.69 billion in 2023 to $12.43 billion in 2024 at a compound annual growth rate (CAGR) of 28.4%. The growth in the historic period can be attributed to government regulations, rise of environmental concerns, automotive industry transformation, reduced battery costs, consumer demand for electric mobility.
The ev platform market size is expected to see…
Family Floater Health Insurance Market 2024 Analysis By Size, Share, Growth, Tre …
"The family floater health insurance market size has grown rapidly in recent years. It will grow from $48.45 billion in 2023 to $53.93 billion in 2024 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to rising healthcare costs, increased health awareness, advancements in medical treatments, family-centric healthcare services, healthcare inflation awareness.
The family floater health insurance market…
Bike Sharing Market Expected to Reach $5.2 Billion by 2028, Fueled by Urbanizati …
The bike sharing market size has grown strongly in recent years. It will grow from $3.82 billion in 2023 to $4.09 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to urbanization and population density, environmental awareness, government initiatives and policies, infrastructure development, health and wellness trends.
The bike sharing market size is expected to see strong growth in…
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand.
Browse 156 Market Data Tables and 112 Figures spread through 175…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited.
Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring…
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year.
Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved…
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018!
Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led…
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion.
One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and…
